dual agonist — my 21-week log, condensed into one table
I have had 5 orders now and I keep a table, so here is the honest summary rather than a vibe.
Material has been consistent. Communication has not. Shipping has varied by about 14 days on nominally the same lane, which matters more in summer than in February.
The independent number came back 97.9% against a claimed 94.2%, which I read as agreement rather than a discrepancy — inter-lab variance on this assay is a point or two either way and treating one lab as ground truth is how people end up in pointless arguments with vendors.
Batch number is in the comments. Ask if you want the method.
best — the order this archive was captured in
The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.
not approved, descriptive posts only
Strongly agree. The safety story is separate.
phase 17 data is interesting, phase 14 will be different
glucagon injection is a different vector than GLP-1
My version of this: I was so worried about the injection that I put it off for eleven days. The injection is the easiest part.
My version of this: I was so worried about the injection that I put it off for eleven days.
Adding to this: biopsy is doing more work than the comment implies.
the GLP-1/glucagon dual is glucagon, different from GIP/GLP-1
phase 9 data is interesting, phase 32 will be different
Yeah, glucagon co-agonism is genuinely different.
Yeah, glucagon co-agonism is genuinely different.
Half-life is about 168 hours, so steady state lands around week 2–5. Practical consequence: what you feel in week 1 is not what that dose does.
glucagon injection is a different vector than GLP-1
Hepatic fat or MASH or what?
Not convinced. The evidence does not support that reading.
glucagon co-agonism has a different safety story
Yeah, glucagon co-agonism is genuinely different.
the safety profile is not just tirzepatide amplified
the heart rate signal is real in the data
the heart rate signal is real in the data
Disagree on that part. 96.8% and 96.2% on the same vial is normal.
Strongly agree. The safety story is separate.
phase 22 data is interesting, phase 16 will be different
Not convinced.
Disagree on that part. 99.2% and 98.9% on the same vial is normal.
Respectfully this is a sample of one presented as a finding.
- 1Not convinced. The evidence does not support that reading.10 comments in this branch · started by u/whois_wanda
- 2i wish i had read this 12 months ago6 comments in this branch · started by u/tired_ledger_ftw